- Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 TranscriptFeb 25, 2024
- Celldex Therapeutics Inc Conference Call & Webcast TranscriptNov 06, 2023
- Celldex Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Celldex Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Celldex Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria TranscriptFeb 26, 2023
- Celldex Therapeutics Inc Barzolvolimab Global Urticaria Forum 2022 Data Presentations and Program Update Call TranscriptDec 06, 2022
- Celldex Therapeutics Inc Corporate Call - Barzolvolimab Interim Phase 1b Multiple Ascending Dose Chronic Spontaneous Urticaria Study Results EAACI 2022 TranscriptJun 30, 2022
- Q4 2021 Celldex Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$29.9 (-0.83%)Earnings
- Celldex Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) TranscriptFeb 16, 2022
- Celldex Therapeutics Inc to Discuss the CDX-0159 Phase 1b Study Results in Cold Urticaria and Symptomatic Dermographism Late Breaking Presentation at EAACI 2021 - Conference Call TranscriptJul 12, 2021
- Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update TranscriptMar 29, 2021
- Q2 2020 Celldex Therapeutics Inc Earnings Call TranscriptAug 06, 2020$11.71 (+1.39%)Earnings
- Celldex Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Q2 2019 Celldex Therapeutics Inc Earnings Call TranscriptAug 07, 2019$2.16 (+3.85%)Earnings
- Q4 2018 Celldex Therapeutics Inc Earnings Call TranscriptMar 07, 2019$4.6 (-1.71%)Earnings
Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Celldex Interim Data Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Sarah Cavanaugh, Senior Vice President of Corporate Affairs. Thank you. Please go ahead, ma'am.
Thank you. Good morning, and thank you all for joining us to discuss the exciting interim data set we reported earlier today from our Phase IB study of CDX-0159 in chronic inducible urticaria. With me on the call today from Celldex are Anthony Marucci, Co-Founder, President and CEO; Dr. Margo Heath-Chiozzi, Senior Vice President of Regulatory Affairs and Medical Lead on the study; Dr. Diane Young, Senior Vice President and Chief Medical Officer; Dr. Tibor Keler, Co-Founder, Executive Vice President and Chief Scientific Officer; and Dr. Diego Alvarado, Senior Director of Research and the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)